Expert Rev Anticancer Ther. 2007 Nov;7(11):1529-36.

Management of Bcr-Abl-positive leukemias with dasatinib.

Source

III. Medizinische Klinik, Abteilung Leukaemieforschung, Medizinische Fakultaet Mannheim, University of Heidelberg, 68167 Mannheim, Germany. hochhaus@uni-hd.de

Abstract

Dasatinib is a novel, potent, multi-targeted kinase inhibitor that is approved in Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute lymphoblastic leukemia following imatinib failure. Clinical trials have demonstrated its activity across all phases of CML. Dasatinib was superior to high-dose imatinib in a randomized, Phase II study of patients with chronic-phase CML who were resistant or intolerant to imatinib. Preliminary data from a Phase II trial in patients with previously untreated CML suggests that dasatinib compares favorably with imatinib in first-line use. Adverse events experienced with dasatinib include myelosuppression and fluid retention (e.g., pleural effusions), which were manageable with dose adjustment or treatment.

PMID:: 18020922; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Chronic Myeloid Leukemia - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. [Clin Ther. 2007]
Review Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M. Clin Ther. 2007 Nov; 29(11):2289-308.
Review Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. [Drugs. 2011]
Review Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL, Keam SJ. Drugs. 2011 Sep 10; 71(13):1771-95.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. [N Engl J Med. 2006]
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, et al. N Engl J Med. 2006 Jun 15; 354(24):2531-41.
Review Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. [Clin Lymphoma Myeloma. 2008]
Review Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Jabbour E, Cortés JE, Kantarjian H. Clin Lymphoma Myeloma. 2008 Mar; 8 Suppl 3:S75-81.
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. [Leukemia. 2008]
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, et al. Leukemia. 2008 Jun; 22(6):1200-6. Epub 2008 Apr 10.

See reviews... See all...

Cited by 4 PubMed Central articles

Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). [Genes Cancer. 2010]
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).
Samanta AK, Chakraborty SN, Wang Y, Schlette E, Reddy EP, Arlinghaus RB. Genes Cancer. 2010 Apr; 1(4):346-59.
Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. [Leukemia. 2010]
Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.
Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, Hunger SP, Devidas M, Children's Oncology Group. Leukemia. 2010 Feb; 24(2):285-97. Epub 2009 Dec 17.
Review The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. [J Hematol Oncol. 2009]
Review The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
Masiello D, Gorospe G 3rd, Yang AS. J Hematol Oncol. 2009 Nov 12; 2:46. Epub 2009 Nov 12.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Management of Bcr-Abl-positive leukemias with dasatinib.
Management of Bcr-Abl-positive leukemias with dasatinib.
Expert Rev Anticancer Ther. 2007 Nov ;7(11):1529-36.

PubMed
MicroRNA expression profiling in cancer from a bioinformatics prospective.
MicroRNA expression profiling in cancer from a bioinformatics prospective.
Expert Rev Mol Diagn. 2007 Nov ;7(6):787-92.

PubMed
[Post-myocardial infarction depression].
[Post-myocardial infarction depression].
An Med Interna. 2007 Jul ;24(7):346-51.

PubMed
The role of anti-IgE therapy in combination with allergen specific immunotherapy...
The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
BioDrugs. 2007 ;21(6):403-10.

PubMed
Lepirudin: a review of its potential place in the management of thrombotic disor...
Lepirudin: a review of its potential place in the management of thrombotic disorders.
BioDrugs. 1998 Sep ;10(3):227-55.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: